Physician

Michael Mohammad Rezaian, M.D.

According to 2025 Medicare claims, Michael Rezaian, M.D. (NPI: 1598821449) practices rheumatology in the Hagerstown-Martinsburg, MD-WV market, with the plurality of this provider's patient population coming from Berkeley, WV. This provider's primary affiliated billing organization is RURAL OUTREACH ARTHRITIS CENTER (NPI: 1568631950; TIN: 232870412) and primary practice location at 25401-8896. Rezaian is affiliated with the ACO West Virginia (ACO ID: A3563) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Rezaian's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 506 traditional Medicare patients, billed 2,218 HCPCS/CPT codes, and received $86,447 in Medicare payments. The top billing code was 99443 (Telephone medical discussion with physician, 21-30 minutes). Part D data shows 4,583 prescription claims across 709 beneficiaries totaling $14,386,644 in drug costs, led by Otezla (Apremilast). 2019 DME data shows 27 claims. Open Payments data shows 9 records totaling $3,726. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $180,705 to $86,447. In contrast, Part D prescription costs have moved sharply higher in recent years, from $3,281,429 to $14,386,644. For DME billing, this smaller-volume category moved up and down with repeated peaks and valleys, starting at $1,336 and ending at $660.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	958	4,411	$180,705
2016	987	5,493	$155,468
2017	949	3,813	$139,588
2018	999	3,220	$163,194
2019	1,068	3,437	$179,930
2020	811	2,080	$126,126
2021	722	2,070	$154,215
2022	657	1,934	$128,846
2023	572	1,853	$109,499
2024	506	2,218	$86,447

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	862	12,173	$3,281,429
2016	924	11,448	$4,342,133
2017	898	9,479	$5,690,582
2018	942	8,759	$5,757,311
2019	1,005	8,754	$5,857,463
2020	856	6,513	$6,060,117
2021	762	5,240	$6,962,112
2022	753	4,439	$9,282,754
2023	692	4,472	$12,442,986
2024	709	4,583	$14,386,644

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	18	$346
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	27	$1,191
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99443	Telephone medical discussion with physician, 21-30 minutes	20	26	$76
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	364	730	$71
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	40	40	$68
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	285	503	$53
99211	Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional	50	93	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Otezla	Apremilast	411	12,418	$2,022,300
Cosentyx Sensoready (2 Pens)	Secukinumab	232	7,182	$1,942,725
Rinvoq	Upadacitinib	276	8,940	$1,875,066
Cosentyx Sensoready Pen	Secukinumab	222	6,209	$1,746,451
Enbrel Sureclick	Etanercept	184	5,376	$1,404,512

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$3,726	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael Mohammad Rezaian, M.D.?

Tedicare shows public-source Medicare data for Michael Mohammad Rezaian, M.D. (NPI 1598821449), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Mohammad Rezaian, M.D. have ACO affiliation data?

Michael Mohammad Rezaian, M.D. is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Michael Mohammad Rezaian, M.D.?

Michael Mohammad Rezaian, M.D. is linked to RURAL OUTREACH ARTHRITIS CENTER (billing NPI 1568631950) in the available physician profile data.

Does Michael Mohammad Rezaian, M.D. have Open Payments data?

Michael Mohammad Rezaian, M.D. has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.